Phase I/II Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Non-Hodgkin's lymphoma vaccine (Primary) ; Agatolimod; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 13 Jan 2020 Biomarkers information updated
- 02 Jan 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2020 as reported by ClinicalTrials.gov.
- 02 Jan 2013 Planned number of patients changed from 30 to 59 as reported by ClinicalTrials.gov.